Bioscientist Royston turns his attention to creating a center in San Diego's crowded research community

Ivor Royston, who at the age of 33 founded Hybritech Inc., the first company in the United States to exploit monoclonal antibodies commercially, and who became a millionaire in the process, is taking his vision for enterprise to a new nonprofit venture.

Among the palm trees, a handful of research institutes, and the 90 biotechnology companies that make San Diego an idyllic place for scientists to work, Royston is opening a clinical research cancer center.

The entrepreneur hopes his small cancer center, with its initial focus on immunotherapy and gene therapy research and clinical care, will flower into a full-fledged research and cancer care facility and be a resource for cancer researchers and oncologists of the 21st century.

Since 1971, when Congress passed the National Cancer Act, legislators and scientists have attempted to address the...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?